First ALS Patient Enters US Study of Radicava’s Impact on Disease Biomarkers

First ALS Patient Enters US Study of Radicava’s Impact on Disease Biomarkers

The REFINE-ALS study, an effort to identify and measure the levels of specific biomarkers in amyotrophic lateral sclerosis (ALS) patients being treated for a first time with Radicava (edaravone), has enrolled its first participant, Mitsubishi Tanabe Pharma America (MTPA) announced.

This observational trial, sponsored by MTPA — which developed and markets Radicava — is being led by the Neurological Clinical Research Institute (NCRI) at Massachusetts General Hospital (MGH) under a collaborative agreement with the company.

“We are honored to be working with so many esteemed collaborators on this novel study and excited to have reached this milestone of enrolling the first patient,” Stephen Apple, MD, senior medical director of medical affairs at MTPA, said in a press release. “This research has great potential to provide a deeper understanding of the biological effects of Radicava.”

REFINE-ALS will enroll about 300 ALS patients across 40 sites in the U.S., and measure the levels of distinct biomarkers involved in oxidative stress — the cellular damage that occurs as a consequence of high levels of oxidant molecules — and in inflammatory response, neuronal injury or death, and muscle injury.

Specialty laboratories, including Oxford BioDynamics and SomaLogic, are also assisting with the study by giving its researchers access to cutting-edge technology. These tools will allow them to evaluate a new class of epigenetic biomarkers — molecules that determine which genes are ‘on’ and ‘off’, without affecting the genetic sequence of DNA — and to measure changes in up to 5,000 proteins throughout the body.

The study is now enrolling adults, age 18 or older, with sporadic or familial ALS. All must be able to be prescribed Radicava, but to not have used it or only to have taken it for one month before being screened to enter the study. Patients will be given six cycles of Radicava as an intravenous (IV) infusion over 24 weeks, with blood and urine samples taken for analyses.

Biomarker levels and ALS progression will be assessed before initiating treatment, at the start of treatment, and at specific times throughout the study. Biomarkers will be compared with information from biorepositories, while evidence of disease progression will be measured against models for ALS.

Interim results of REFINE-ALS are expected to be announced next year.

“ALS is a multifaceted and complex disease with few treatment options,” said James Berry, MD, MPH, primary investigator of the study at MGH NCRI. “We’re proud to be investigating the biological impact of Radicava on this disease using a combination of genomic analysis and cutting edge biomarker platforms, potentially enhancing our understanding of the disease and its treatments and improving clinical treatment plans for people with ALS.”

Total Posts: 5
Inês Martins holds a BSc in Cell and Molecular Biology from Universidade Nova de Lisboa and is currently finishing her PhD in Biomedical Sciences at Universidade de Lisboa. Her work has been focused on blood vessels and their role in both hematopoiesis and cancer development.
Average Rating
5 out of 5 stars. 4 votes.
My Rating:

6 comments

  1. Dave Reckonin says:

    This is interesting and a useful development.
    What would be even more informative would be reports of efficacy of Radicava since it was given FDA approval for use with pALS.
    Phase 3 trials seemed to suggest that, on average, longevity was improved by about 33%. Is that proving consistent given the huge increase in the numbers of pALS receiving it ?
    Why is MT so quiet on this apart of course from,some time ago, verbally claiming that one pALS described its effect as ‘miraculous’?

  2. Cindy says:

    Dave I too wonder why this hasn’t been tracked from the beginning. I’ve been on radicava for 2 years having been diagnosed with slowly progressive form. My legs have gradually gotten weaker and weaker but it seems to be only in my legs. I attribute it to be radicava but who knows for sure.

  3. Bill says:

    I agree with the commentors. With thousands of people actually on Radicava, why isn’t data gathered on actual efficacy? Same with Riluzole. We know the answer…….there is no money in it for the researchers. Forget the anecdotal “evidence “.

  4. Tania says:

    My daughter Zoie has als here in Perth Australia. Is there any way I can get her on this trail . She has had it for 61/2 years. She is starting to detract.We need help here not only my child but for all Australians .a lot don’t know they have Als as there is only one major hospital thati

Leave a Comment

Your email address will not be published. Required fields are marked *